The Markers That Matter. The Decision That Counts.
SkylineDx is dedicated to improve therapeutic decision making through the development of reliable, clinically validated molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
SkylineDx and leading institutes present three abstracts on multiple myeloma risk stratification
New Start for SkylineDx with Van Herk Investment Skyline Diagnostics, a Rotterdam-based company in
Skyline's article 'A standardized microarray assay for the independent gene expression markers
The AMLprofiler microarray assay employs a two-step classifier to detect double mutations